Teva sees lower revenue, higher profit in 2015

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) introduced 2015 financial guidance on Thursday that projects net revenues below Street expectations but offers the prospect of better EPS due to cost cutting and product launches in its specialty drug portfolio.

The company expects 2015 net revenues of $19-$19.4 billion, below analyst estimates of about $20.1 billion. At $5-$5.30, the top end of the range for non-GAAP diluted EPS bests the Street's estimate of $5.06. ...